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SUMMARY
Plasmodium parasites are highly selective when infecting hepatocytes and induce many changes 
within the host cell upon infection. While several host cell factors have been identified that are 
important for liver infection, our understanding of what facilitates the maintenance of infection 
remains incomplete. Here, we describe a role for phosphorylated ribosomal protein S6 
(Ser235/236) (p-RPS6) in Plasmodium yoelii-infected hepatocytes. Blocking RPS6 
phosphorylation prior to infection decreases the number of liver stage parasites within 24 h. 
Infected hepatocytes exhibit elevated levels of p-RPS6 while simultaneously abrogating the 
induction of phosphorylation of RPS6 in response to insulin stimulation. This is in contrast with 
the regulation of p-RPS6 by Toxoplasma gondii, which elevates levels of p-RPS6 after infection 
but does not alter the response to insulin. Our data support a model in which RPS6 
phosphorylation is uncoupled from canonical regulators in Plasmodium-infected hepatocytes and 
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After mosquito-to-human transmission, Plasmodium parasites infect hepatocytes. Glennon et al. 
demonstrate that infected cells exhibit elevated levels of ribosomal protein S6 phosphorylation, 
and this phosphorylation appears uncoupled from canonical regulators. This work raises the 
possibility that Plasmodium-infected hepatocytes are governed by non-canonical, re-wired signal 
transduction cascades.
INTRODUCTION
Plasmodium parasites are the causative agents of malaria and inflict substantial disease 
worldwide. Malaria disease is caused by the intraerythrocytic forms of the parasite, which 
multiply rapidly in the blood, causing fever, anemia, and complications in multiple organs 
(Trampuz et al., 2003). To establish intraerythrocytic infection, parasites first interact with 
the dermis (Gueirard et al., 2010), enter the circulation, travel to the liver, and then undergo 
obligate intracellular development within the liver. Unlike other apicomplexan parasites, 
particularly Toxoplasma gondii, when Plasmodium parasites are transmitted to the human 
host, they are exquisitely selective for their first host cell, the hepatocyte. No clinical 
symptoms are associated with liver stage (LS) infection, and parasite numbers are extremely 
low, suggesting that this point of development represents a bottleneck for the parasite 
(Vaughan et al., 2008). Thus, LS represents an attractive target for intervention.
During LS infection, intracellular parasites dramatically alter the biology of their hepatocyte 
host cells. For example, LS parasites divide tens of thousands of times, stretching the host 
cell to 50–100 times its normal volume, despite the presence of regulatory pathways that 
carefully control hepatocyte size (Sinturel et al., 2017). Hepatocytes initiate a range of host 
defense pathways upon Plasmodium infection, including apoptosis (Kaushansky et al., 
2013), autophagy (Thieleke-Matos et al., 2016), and multiple classical innate immune 
responses such as the Type I interferon response (Liehl et al., 2014, 2015; Miller et al., 
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2014). Moreover, not all hepatocytes have an equivalent capacity to support sporozoite 
infection. Human hepatocytes from different donors show differential susceptibility in vitro 
(March et al., 2013), and mice of different strains have dramatically different susceptibilities 
to LS infection, even those that are genetically closely related (Khan and Vanderberg, 1991; 
Scheller et al., 1994). Specifically, hepatocytes from the mouse substrain BALB/cByJ 
exhibit a 2- to 5-fold increased susceptibility compared to those from BALB/cJ mice 
(Kaushansky et al., 2015a). Even within a single animal, cellular properties, such as the 
DNA content of hepatocytes, have been associated with infection, as polyploid hepatocytes 
are more susceptible to infection than diploid hepatocytes (Austin et al., 2014). Polyploidy is 
a common feature of hepatocytes in both mice and humans and is thought to play a role in 
liver regeneration (Øvrebø and Edgar, 2018).
The specific host factors supporting parasite development are not comprehensively 
understood; however, several hepatocyte membrane proteins, including EphA2, CD81, and 
SR-BI, have been identified to play a significant role in mediating parasite invasion 
(Kaushansky et al., 2015b; Silvie et al., 2006; Yalaoui et al., 2008). Once a parasite is inside 
a hepatocyte, its survival is also influenced by host cell factors, including levels of the tumor 
suppressor p53 (Douglass et al., 2015; Kaushansky et al., 2013), the degree of endoplasmic 
reticulum (ER) stress (Inácio et al., 2015; Kaushansky and Kappe, 2015), and regulation of 
an extensive network of kinases (Arang et al., 2017; Prudêncio et al., 2008; Ruivo et al., 
2016). Interestingly, a large portion of the hepatocyte kinome regulates LS infection (Arang 
et al., 2017), suggesting that phosphosignaling in the cell might be globally altered in the 
context of infection. Consistent with this hypothesis, a variety of signaling pathways are 
disrupted by Plasmodium infection on the transcriptional, protein, and post-translational 
levels (Albuquerque et al., 2009; Kaushansky et al., 2013; Posfai et al., 2018). However, the 
extent to which the parasite manipulates its host environment remains largely unexplored, 
and the mechanisms for how the parasite interacts directly with the signaling milieu remains 
poorly defined.
RESULTS AND DISCUSSION
Reverse Phase Protein Arrays Identify Cellular Disruptions in Susceptible Hepatocytes
We reasoned that a systematic evaluation of hepatocytes that exhibited differential 
susceptibility to infection might provide insight into conserved hepatocyte factors that 
regulate Plasmodium LS infection. Since hepatocytes isolated from BALB/cJ mice are less 
susceptible to infection than hepatocytes isolated from BALB/cByJ mice (Kaushansky et al., 
2015a), and hepatocytes with elevated ploidy exhibit higher susceptibility to infection 
(Austin et al., 2014), we chose to compare both populations of differentially susceptible 
hepatocytes to identify factors that control LS infection. A limited set of transcriptional 
differences between hepatocytes of different susceptibilities, both polyploid (Lu et al., 2007) 
and BALB/c substrain (Kaushansky et al., 2015a), have been identified. However, mRNA is 
not always an accurate readout for protein and post-translational changes, and differences in 
the proteomes of BALB/cJ and BALB/cByJ mice or diploid and polyploid hepatocytes have 
not been characterized. To assess differences between these hepatocyte populations, we 
chose to use reverse phase protein microarrays (RPPAs), which enable broad but targeted 
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interrogations of changes on the protein and post-translational levels (Sevecka et al., 2011) 
using cellular lysates deposited in nanoliter droplets on nitrocellulose-coated glass slides. 
Levels of specific proteins or their post-translational modifications can be detected by 
probing the printed lysates with a panel of validated antibodies (Kaushansky et al., 2013; 
Paweletz et al., 2001; Sevecka et al., 2011). This approach allows the analysis of up to 
hundreds of proteins and post-translational modifications in parallel (Paweletz et al., 2001; 
Sevecka et al., 2011).
To investigate the molecular differences between polyploid and diploid hepatocytes, and 
between BALB/cByJ and BALB/cJ livers, we probed RPPAs derived from high-
susceptibility (8n hepatocytes and BALB/cByJ livers) and low-susceptibility (2n hepatocytes 
and BALB/cJ livers) populations with 62 antibodies that target proteins involved in cellular 
outcomes previously implicated in Plasmodium infection. These included regulators of 
survival, apoptosis, autophagy, cell proliferation, and cell-cycle control (Table S1).
Protein lysates were obtained from 8n and 2n primary mouse hepatocytes (BALB/cAnN) 
and from BALB/cJ and BALB/cByJ mouse livers. RPPAs were fabricated using a contact 
microarrayer, which served to deposit lysates onto nitrocellulose pads. Arrays were then 
probed with antibodies to obtain quantitative information on changes in host cell total or 
modified protein abundance. In addition to the protein or post-translational modification of 
interest, each array was also probed with an antibody against β-actin, which was used as a 
surrogate for total protein quantity. The signal from the antibody of interest was normalized 
to the signal from b-actin (Figures 1A and 1B).
Several proteins were significantly upregulated in BALB/cByJ livers (Figure 1; Table 1). Of 
these differentially regulated proteins and post-translational modifications, only one was 
significantly elevated in both 8n cells and BALB/cByJ livers—ribosomal protein S6 (RPS6) 
phosphorylated on serine residues 235 and 236 (p-RPS6). To verify these findings, we 
evaluated levels of p-RPS6 in hepatocytes that differ in level of ploidy by flow cytometry 
and levels of p-RPS6 in BALB/cJ and BALB/cByJ livers via western blot (Figure S1). We 
found elevated levels of p-RPS6 in both BALB/cByJ livers and in Hepa 1–6 cells with high 
DNA content.
Small Molecule Inhibition of p-RPS6 prior to Infection Decreases Parasite Burden In Vitro 
and In Vivo
RPS6 is an essential part of the 40S subunit of the eukaryotic ribosome (Gressner and Wool, 
1974). It is phosphorylated on five serine residues (Bandi et al., 1993; Krieg et al., 1988) 
through the activation of two central cell signaling pathways: the AKT/PI3K 
(phosphoinositol-3-kinase) pathway (Wettenhall et al., 1992) and the MEK/ERK mitogen-
activated protein kinase (MAPK) pathway (Pende et al., 2004). RPS6 phosphorylation is 
largely regulated by the activity of two kinases: p70 S6 kinase (P70S6K) and p90 RSK 
kinase (P90S6K), both of which phosphorylate RPS6 on Ser235/236. RPS6 phosphorylation 
has been linked to cell size and proliferation (Pende et al., 2000; Ruvinsky et al., 2005), 
clearance of apoptotic cells (Jeon et al., 2008), and protection against DNA damage in 
cancerous cells (Khalaileh et al., 2013; Wittenberg et al., 2016). RPS6 has also been linked 
to regulation of free amino-acid levels (Ruvinsky and Meyuhas, 2006), glucose homeostasis 
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(Pende et al., 2000; Ruvinsky et al., 2005), and lipid biosynthesis (Calvisi et al., 2011), all of 
which are important for parasite growth (Itani et al., 2014; Itoe et al., 2014; Meireles et al., 
2017).
To determine whether phosphorylation of RPS6 has functional consequences for 
Plasmodium LS infection, we treated Hepa1–6 cells with BI-D1870, a P90S6K inhibitor 
(Sapkota et al., 2007), or LY2584702, an inhibitor of all P70S6K isoforms (Tolcher et al., 
2014), for 20 h before infection with P. yoelii sporozoites and then throughout the infection. 
Pre-treatment with LY2584702 decreased the phosphorylation of RPS6 in uninfected cells, 
both at basal levels and in the context of insulin treatment (Figures S2A and S2B). BI-
D1870, however, only reduced RPS6 phosphorylation modestly in the context of insulin 
treatment (Figures S2A and S2B). Treatment with either inhibitor did not impact host cell 
viability after 24 or 48 h (Figure S2C). Ninety minutes after P. yoelii infection, there was no 
significant difference in infection rate (Figure 2B). However, at both 24 and 48 h post-
infection (hpi), each inhibitor significantly lowered LS numbers (Figure 2B). These data are 
consistent with a model where RPS6 regulates maintenance of Plasmodium LS infection 
after initial invasion. To better characterize when inhibition of RPS6 influences the survival 
of LS parasites, we treated cells at various time points throughout the infection process 
(Figure 2A). Drug treatment of cells from 20 h before infection through invasion 
significantly reduced LS burden at 24 hpi (Figure 2C). Adding inhibitors immediately after 
invasion (Figure 2D) or during invasion (Figure 2E) did not have any effect on infection at 
24 h. Finally, incubation of sporozoites with inhibitors before adding them to cells had no 
effect on LS burden after 24 h (Figure 2F), suggesting that the inhibitors are not acting 
directly on the parasite. Pre-treatment of cells with insulin, which stimulates 
phosphorylation of RPS6 (Figures S2D and S2E), increased sporozoite invasion levels after 
90 min (Figure S2F). These data are consistent with the hypothesis that p-RPS6, or a process 
regulated by or in parallel with p-RPS6, is important for the selection of cells that are 
hospitable for maintenance of infection. Due to the potential for off-target effects of BI-
D1870 (Neise et al., 2013; Roffé et al., 2015), we used short hairpin RNAs (shRNAs) to 
knock down P90S6K and then measured LS burden after 24 h. Knockdown of P90S6K by 
85% reduced LS burden in Hepa1–6 cells by an average of 25% (Figures S3A and S3B). 
P90S6K knockdown did not reduce cell viability compared to scramble controls (Figure 
S3C). We were unable to generate stable hepatocyte lines upon prolonged knockdown of 
P70S6K.
Finally, we assessed the impact of RPS6 phosphorylation on Plasmodium infection in vivo. 
We treated mice with BI-D1870 or LY2584702 for 24 h and then infected them with P. yoelii 
sporozoites expressing a GFP-luciferase fusion protein (Miller et al., 2014) by intravenous 
injection. Treatment with each inhibitor was continued daily until the end of the experiment. 
Animals were injected with D-luciferin, which allowed LS burden to be monitored by 
bioluminescent in vivo imaging at 44 h after infection. At this time, livers were also 
harvested for histological analysis. Mice treated with LY2584702 exhibited significantly 
lower luciferase signal when compared to the vehicle control. In contrast, the administration 
of BI-D1870 had no effect (Figure S3E). The difference of activity observed in BI-D1870 in 
vitro and in vivo could originate from a multitude of factors. First, the bioavail-ability, 
pharmacokinetics, or off-target effects of the compound in vivo may alter its activity. 
Glennon et al. Page 5













Moreover, transformed Hepa1–6 cells in vitro may exhibit altered responses to primary 
hepatocytes found in vivo. Microscopic investigation of LS parasite burden demonstrated 
that treatment with neither BI-D1870 nor LY2584702 affected the size of parasites (Figure 
S3F), suggesting that RPS6 acts to curtail parasite infection by eliminating infected 
hepatocytes or by eliminating whole parasites within infected hepatocytes, rather than 
diminishing the growth of LS parasites.
RPS6 Activation in Infected Hepatocytes
Considering the absence of effect of p-RPS6 inhibition post-invasion, we asked whether p-
RPS6 levels are elevated in infected cells. Increased phosphorylation of RPS6 has been seen 
in the context of infection with several other pathogens (Bell et al., 2017; Jakubowicz and 
Leader, 1987), including Toxoplasma gondii (Wang et al., 2009). In T. gondii-infected cells, 
p-RPS6 levels are elevated from 2 through 24 hpi. It has been proposed that this is due to the 
activity of mammalian target of rapamycin (mTOR), which signals through P70S6K and is 
localized to the parasitophorous vacuole (Wang et al., 2009). We infected Hepa1–6 cells 
with P. yoelii sporozoites and measured levels of p-RPS6 in infected and uninfected cells 3, 
6, and 24 hpi. Infected cells exhibited significantly elevated levels of p-RPS6 compared to 
uninfected cells at all time points (Figure 3; Figure S4D). In contrast, cells mock-treated 
with material from uninfected mosquito salivary glands did not exhibit altered p-RPS6 levels 
(Figure S4A). We also observed higher levels of total RPS6 protein in P. yoelii-infected cells 
24 hpi (Figure S4E). Due to the selective nature of Plasmodium sporozoite invasion, the 
elevated levels of p-RPS6 observed in infected cells could be due to invasion of hepatocytes 
that maintain high levels of p-RPS6 or to parasite perturbation of RPS6 expression and 
phosphorylation.
To better understand how levels of p-RPS6 are maintained in infected cells, we asked 
whether phosphorylation of RPS6 is regulated by the canonical signaling pathway involving 
phosphorylation of AKT and P70S6K in infected cells (Figure 4A). In response to growth 
factor stimuli such as insulin, phosphorylation of the insulin receptor leads to the 
recruitment of adaptor proteins, which activate PI3K and lead to the phosphorylation of 
AKT. Activation of AKT promotes the phosphorylation of P70S6K, which, in turn, 
phosphorylates RPS6 (Figure 4A) (reviewed in Meyuhas, 2015; Tavares et al., 2015). To 
evaluate whether elevated p-RPS6 resulted from this canonical signaling cascade, we again 
used RPPA. We treated cells with insulin and collected protein lysates at 5 separate time 
points between 3 and 48 hpi. Ly-sates were printed on nitrocellulose pads and probed with 
antibodies against p-AKT (pThr308), p-P70S6K (pThr389), and p-RPS6 (pSer235/236) to 
obtain quantitative information on changes in phosphorylated protein abundance. Linearity 
of protein detection by RPPA with these antibodies was assessed by comparing the signal 
from each antibody with that obtained by western blot. Each antibody exhibited a linear 
relationship between signals obtained by western blot and by RPPA (Figure S5).
We next assessed the relationship between different components of the pathway. We 
reasoned that signaling through the p-AKT/p-P70S6K/p-RPS6 axis would result in tightly 
correlated values of each phosphorylation site. Indeed, when we stimulated cells with insulin 
and lysed them between 3 and 48 hpi, we see correlations between each pairwise 
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combination of p-AKT, p-P70S6K, and p-RPS6 (Figure 4B). This is consistent with the 
well-established model that these kinases act within the same signal transduction cascade.
While insulin treatment is a simple and common cell stimulation, the infection of any 
vacuole-contained intracellular pathogen might alter signaling in both canonical and 
surprising ways. To determine whether the associations across this signal transduction 
cascade are conserved in the context of Plasmodium infection, we infected Hepa1–6 cells 
with GFP-expressing P. yoelii sporozoites and collected infected samples at 3, 6, 12, 24, and 
48 h after infection by fluorescence-activated cell sorting (FACS). As a control, we collected 
uninfected cells from the same infected well. We lysed each population of cells and printed 
the lysates on nitro-cellulose-coated glass slides for use in the RPPA. Slides were probed, as 
described earlier, with antibodies against p-AKT (pThr308), p-P70S6K (pThr389), and p-
RPS6 (pSer235/236). Interestingly, in infected cells, phosphorylation of AKT, P70S6K, and 
RPS6 no longer appeared to be correlated (Figure 4B), suggesting that the canonical 
relationships between molecules within this signaling cascade are disrupted in Plasmodium-
infected cells. The lack of correlation between p-P70S6K and p-RPS6 is particularly 
striking, as RPS6 is a substrate of P70S6K (Ruvinsky and Meyuhas, 2006).
One might presume that any pathogen that perturbs levels of p-RPS6 may exhibit altered 
associations between components of the p-AKT/p-P70S6K/p-RPS6 cascade. To test this 
hypothesis, we infected Hepa1–6 cells with the related apicomplexan parasite Toxoplasma 
gondii, which also resides within a vacuole inside the host cell, and collected samples at 3, 6, 
12, 24, and 48 hpi. We then deposited these lysates on nitrocellulose-coated glass slides and 
evaluated levels of p-AKT, p-P70S6K, and p-RPS6 by RPPA. In T. gondii-infected cells, as 
in insulin-stimulated cells, we observed a correlation between levels of p-RPS6 and p-
P70S6K (Figure 4C). Thus, the disruption of association between members of this signaling 
pathway is not the result of a non-specific effect of any intracellular apicomplexan and might 
be unique to Plasmodium infection.
RPS6 Is Not Phosphorylated in Response to Insulin in Plasmodium-Infected Cells
To examine the level of p-RPS6 on the single cell level, and without the delay caused by 
sorting infected cells, we used flow cytometry to measure the effect of infection on insulin-
induced p-RPS6. Hepa1–6 cells were infected with P. yoelii or T. gondii. After 24 h, infected 
(or uninfected) cells were treated with insulin for 30 min before fixation. Cells were then 
processed for flow cytometry. As seen previously (Figure 3), P. yoelii-infected cells 
exhibited elevated levels of p-RPS6 at 24 h (Figure 5A).T. gondii-infected cells also had 
similarly increased p-RPS6 levels at 24 h (Figure 5C), consistent with what has been seen in 
other cell types (Wang et al., 2009). Insulin-treated uninfected cells had significantly higher 
levels of p-RPS6 than non-treated cells (Figure 5D). However, in P. yoelii-infected cells, 
insulin treatment did not significantly increase p-RPS6 (Figure 5B). In comparison, insulin 
treatment of T. gondii-infected cells significantly increased p-RPS6 levels compared to 
infected but untreated cells (Figure 5D). Mock infections for either pathogen did not alter p-
RPS6 levels or prevent an increase in response to insulin (Figures S4B and S4C).
The additive effect of infection and insulin treatment that we observed during T. gondii 
infection suggests that AKT/P70S6K/RPS6 signaling remains intact during T. gondii 
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infection. In contrast, our data are consistent with a model where AKT/P70S6K/RPS6 
signaling loses its normal connectivity in P. yoelii-infected cells, either due to parasite 
manipulation or pre-selection of hepatocytes with alternate p-RPS6 regulation by 
sporozoites. The lack of response to insulin in P. yoelii-infected cells is unlikely to be due to 
saturation of RPS6 phosphorylation—since we observed similar levels of RPS6 
phosphorylation in response to T. gondii (Figures 5A and 5C) and increased total RPS6 
levels in P. yoelii-infected cells (Figure S4E)—but instead, due to the nature of the infection, 
or the infected cell, itself. Taken together, the data are consistent with a model where 
Plasmodium infection activates RPS6 while simultaneously disrupting the ability of P70S6K 
to do so (Figure 5E). Supporting this model is our finding that levels of p-P70S6K and p-
RPS6 are not correlated during Plasmodium infection (Figure 4) and the observation that 
insulin treatment does not lead to the activation of p-RPS6 during Plasmodium infection 
(Figure 5B). Finally, this model is consistent with the observed effect of the P70S6K 
inhibitor, LY2584702. Inhibition of P70S6K before infection and rewiring of signaling 
networks by the parasite (Figures 2B and 2C)—but not after infection (Figure 2D) when, we 
hypothesize, parasites have already altered the signaling network—decreases the number of 
LS-infected hepatocytes. The mechanism by which Plasmodium may exert control over its 
host hepatocyte remains unknown.
Alternatively, Plasmodium sporozoites may preferentially infect hepatocytes that have 
higher basal levels of RPS6 phosphorylation and altered connectivity between P70S6K and 
RPS6 and, thus, are insensitive to insulin stimulation. Under this scenario, pre-treatment 
with S6K inhibitors may prevent sporozoites from invading the proper host cells, leading to 
infection failure and the reduction in LS burden we see by 24 hpi.
Plasmodium LS infection remodels the host hepatocyte, including physical and 
transcriptional changes (Albuquerque et al., 2009; Kaushansky et al., 2013; Zuck et al., 
2017; Posfai et al., 2018). Optimal maintenance of LS infection is dependent on the activity 
of a large number of host kinases regulating processes such as cytoskeletal organization and 
apoptosis (Arang et al., 2017). These observations are consistent with the hypothesis that the 
parasite rewires a portion of host cell signaling in a manner that disrupts canonical signal 
transduction cascades. Our observation that the insulin/AKT/RPS6 pathway, which has been 
described across metazoans, is disrupted in Plasmodium-infected cells suggests that the 
regulation of even well-conserved pathways may be heterogeneous across individual cells 
and may be susceptible to being coopted by the parasite. RPS6 regulates a plethora of host 
cell processes that may regulate successful LS infection, including cell growth and glucose 
and lipid availability. Plasmodium manipulation of AMPK phosphorylation, a major 
regulator of nutrient homeostasis, during LS infection (Ruivo et al., 2016) and a role for host 
diet in influencing parasite survival in the liver (Zuzarte-Luís et al., 2017) were also recently 
described, suggesting that the metabolic state within the liver is crucial for determining 
infection outcome. By developing within a cell with high RPS6 phosphorylation, 
disconnected from canonical upstream regulators, Plasmodium parasites may be ensuring an 
environment favorable to their development, either through selection or manipulation.
The extent of pathway alterations in hepatocytes during Plasmodium infection, as well as the 
portion of these alterations that are mediated by direct contact with parasite molecules, 
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remains to be explored. By gaining a better understanding of what host proteins are essential 
for LS infection, and how signaling within hepatocytes is altered by infection, we will 
elucidate the process by which the host cell environment is selected for, and manipulated by, 
Plasmodium and identify targets for intervention.
STAR⋆METHODS
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to the Lead 
Contact, Alexis Kaushansky (alexis.kaushansky@seattlechildrens.org).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines and cell culture—In vitro, Hepa1–6 cells were used for P. yoelii infections 
and western blots. Cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) 
complete media (Cellgro), supplemented with 10% FBS (Sigma-Aldrich), 100IU/ml 
penicillin (Cellgro), 100mg/ml streptomycin (Cellgro), and 2.5mg/ml Fungizone (HyClone/
Thermo Fisher).
Experimental animals—Female BALB/cAnN mice (6–8 weeks old) were purchased 
from Harlan Laboratories. Female BALB/cJ and BALB/cByJ (6–8 weeks old) were 
purchased from Jackson Laboratories. All mice were maintained in accordance with 
protocols approved by Center for Infectious Disease Research Institutional Animal Control 
and Use Committee (IACUC).
Mosquito rearing and sporozoite production—For Plasmodium sporozoite 
production, female 6–8-week-old Swiss Webster mice (Harlan) were injected with blood 
stage P. yoelii 17XNL or PyGFP-Luc (Miller et al., 2013) parasites to begin the growth 
cycle. Animal handling was conducted according to the Institutional Animal Care and Use 
Committee-approved protocols. Infected mice were used to feed female Anopheles stephensi 
mosquitoes after gametocyte exflagellation was observed. Salivary glands were dissected at 
days 14 or 15 post blood meal. Sporozoites were isolated by mechanical grinding of pooled 
salivary glands, followed by centrifugation for 2 minutes at 800 RPM and collection of 
supernatant.
T. gondii production and infection—T. gondii strain RHDHXGPRT Gra2:GFP, 
Tub:bgal, was maintained by continual cycling through human foreskin fibroblasts (HFF). 
Parasites were lysed from HFFs by passing 2x through a 27-gauge needle. 1.5 × 105 
parasites were used to infect 5 × 105 Hepa1–6 cells in a 24-well plate for 90 min before cells 
were washed and media replaced.
METHOD DETAILS
Small molecule treatment—BI-D1870 and LY2584702 (SelleckChem) were 
resuspended in DMSO at a stock solution of 10 mM (BI-D1870) or 1 μM (LY2584702). 
Stocks were diluted into cell media to 1 mM (BI-D1870) or 100 nM (LY2584702) and 
added to Hepa1–6 cells. Cells were treated 22 h previous to infection or immediately after 
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infection, as indicated, and media and treatment refreshed every 24 h thereafter. Insulin-
transferrin-sodium selenite (ITSS) was resuspended in water at a stock solution of 5mg/mL. 
Cells were treated at a final concentration of 0.5 ug/mL. Live-dead assays were performed 
using trypan blue staining (Sigma-Aldrich).
Hepatocyte isolation and processing—Hepatocytes were isolated from mice using a 
two-step perfusion in situ. Portal veins of anesthetized mice were cannulated with warmed 
perfusion buffer (1x HBSS w/o calcium, magnesium supplemented with 8 mM HEPES 
buffer and 0.5 mM EDTA) at low flow rate. Once cannulated, the inferior vena cava was 
severed to blanch the liver. The buffer flow rate was increased to 5 mL/min and allowed to 
perfuse for five min with occasional clamping and releasing of the vena cava to inflate the 
liver. The liver was then perfused with 2% collagenase II (Worthington) in collagenase 
buffer (HBSS supplemented with 8 mM HEPES and 0.5 mM CaCl2) for five min at 5 mL/
min. The liver was then removed from the abdominal cavity and the gall bladder excised. 
The liver was placed in a dish of DMEM without serum and gently pushed through a 100-
micron cell strainer to dissociate the hepatocytes, which were then collected with a wide-
bore syringe. The liver cell suspension was centrifuged at 50x g, and the remaining pellet 
washed in DMEM without serum. This step was repeated twice until the supernatant was 
clear, to isolate hepatocytes from cell debris and non-parenchymal cells.
Reverse phase protein microarray—For BALB/c substrains, whole livers from 
BALB/cJ and BALB/cByJ mice (n = 10 per strain) were briefly rinsed in a 20 mM 
HEPESKOH, pH 7.4 buffer before being plunged into liquid nitrogen and snap frozen. 
Frozen livers were weighed and then sequentially cryomilled under liquid nitrogen in a 
Retsch PM 100 planetary ball mill. The jar was cooled in liquid nitrogen in between milling 
cycles. An additional three cryomilling cycles of same duration were performed with twenty 
10 mm stainless steel balls. Cryomilling reduces the liver to a powder of exceptional 
fineness with < 1 – 0.1 μm sized grindate, as judged by light microscopy. Powder was then 
reconstituted in SDS Lysis Buffer (2% SDS, 50 mM Tris-HCl, 5% glycerol, 5 mM EDTA, 1 
mM NaF, 10 mM β-glycerophosphate, 1 mM PMSF, 1 mM activated Na3VO4, 1 mM DTT, 
1% phosphatase inhibitor cocktail 2 (Sigma Aldrich) and 1% phosphatase inhibitor cocktail 
3 (Sigma-Aldrich), 1% PhosSTOP Phosphatase Inhibitor Cocktail Tablet (Roche)), and 
stored at −80°C. To isolate hepatocytes of differing ploidy, livers of BALB/cAnN mice were 
perfused and processed as described above. Cells were stained for DNA content with 
Vybrant DyeCycle Orange (Invitrogen) in DMEM without serum and sorted on a BD Influx 
(BD Biosciences).
Custom lysate microarrays were printed using an Aushon Biosystems 2470 arrayer (Aushon 
Biosystems) on 16-pad nitrocellulose-coated glass slides (Grace Bio-Labs). Lysates were 
arrayed at 333 μM spacing using solid 110 μM pins, which resulted in an average feature 
diameter of 170 μM. Lysates were arrayed in quadruplicate technical replicates. Slides were 
then stored dry, in the dark, and at room temperature until probing. Slides were probed and 
quantified as previously described by Sevecka et al. (2011). Slides were washed with 0.1% 
Tween-20 in PBS (PBST) three times for 5 min each and then incubated in Tris/HCL (pH 9) 
over night. Slides were washed again with PBST and centrifuged to dry. Slides were blocked 
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with 5% BSA in PBST for 1 h at 4°C. Silicon gaskets and bottomless 16-well plates (Grace 
Bio-Labs) were attached and microarrays incubated in primary antibodies. Each microarray 
was probed with a rabbit antibody against the target protein (See Table S2 for antibody list) 
and mouse anti-b-actin (Cell Signaling Technologies) at 1:1000 in 5% BSA in PBST for 24 
hours at 4°C. The antibodies chosen were previously validated to minimize this cross-
reactivity. Slides were washed three times with PBST and incubated with secondary 
antibodies AlexaFluor-647 donkey anti-rabbit and AlexaFluor-555 goat anti-mouse 
(ThermoFisher) at 1:1000 in 5% BSA in PBST for 24 h at 4°C. Slides were washed again 
and centrifuged dry. Slides were scanned using an Axon Genepix 400B Scanner. Spots were 
identified and intensities quantified using Innopsis Mapix software.
In vitro immunofluorescence and quantification—3 × 105 Hepa1–6 cells were 
seeded in each well of an 8-well Permanox chamber slide (NUNC Inc.). Cells were infected 
with 5 × 104 P. yoelii 17XNL sporozoites. Slides were centrifuged for 3 min at 515g in a 
hanging-bucket centrifuge to aid in sporozoite invasion. After 90 min, media containing 
extracellular sporozoites was aspirated, and fresh media containing drug or vehicle, was 
added. Media and drugs were changed every 24 h. LSs developed for 24 or 48 h, at which 
time cells were fixed with 10% formalin, blocked and permeabilized for 1 in PBS containing 
0.1% Triton X-100 and 2% bovine serum albumin (BSA). Staining steps were performed in 
PBS supplemented with 2% BSA. Cells were stained using anti-sera to Plasmodium heat 
shock protein 70 (HSP70) at 4°C overnight, then visualized with the use of AlexaFluor-488 
goat anti-mouse secondary antibody (Invitrogen). Cells were stained with DAPI to visualize 
both hepatocyte and parasite nuclei.
Flow cytometry of infected and uninfected cells—5 × 105 Hepa1–6 cells were 
seeded in each well of a 24-well plate (Corning). After infection and/or treatment cells were 
harvested with 0.25%Trypsin-EDTA and fixed with Cytoperm/Cytofix (BD Biosciences). 
The cells were blocked with Perm/Wash (BD Biosciences) +2% BSA for one h at room 
temperature then stained overnight at 4 C with primary antibodies. Cells were washed three 
times with PBS then stained for one hour at room temperature with secondary antibodies. 
The cells were washed and suspended in PBS+5 mM EDTA. For ploidy measurements, 
RNase A (0.1 mg/mL) and FxCycle Far Red Stain (Invitrogen) were added to the 
resuspension medium. Infection rate, protein signal, and DNA content were measured by 
flow cytometry on an LSRII (Becton-Dickson) and analyzed by FlowJo (Tree Star). 
Antibodies used include rabbit anti-p-RPS6 (S235/6) at 1:200 (Cell Signaling Technologies), 
mouse anti-RPS6 at 1:100, (Cell Signaling Technologies), mouse anti-β-actin (Cell 
Signaling Technologies), T. gondii P30 mouse monoclonal antibody at 1:1000 (Novus 
Biologicals), goat anti-mouse conjugated to AlexaFluor 488 (Invitrogen) at 1:1000, donkey 
anti-rabbit conjugated to AlexaFluor 647 (Invitrogen) at 1:1000, and a monoclonal antibody 
to P. yoelii Circumsporozoite protein (CSP) conjugated to AlexaFluor 488 (Life 
Technologies) at 1:500. Anti-b-actin and anti-p-RPS6 antibodies were not cross-reactive 
with extracellular P. yoelii sporozoites or T. gondii tachyzoites (Figure S6).
Immunofluorescence Microscopy—Extracellular sporozoites and tachyzoites were 
fixed and stained with antibodies as described above. Images were acquired with a 100 × 1.4 
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NA objective (Olympus) on a DeltaVision Elite High Resolution Microscope (GE 
Healthcare Life Sciences). The sides of each pixel represent 64.5 × 64.5 nm and z stacks 
were acquired at 300 nm intervals. Approximately 10 slices were acquired per image stack. 
For deconvolution, the 3D datasets were processed to remove noise and reassign blur by an 
iterative Classic Maximum Likelihood Estimation widefield algorithm provided by Huygens 
Professional Software (Scientific Volume Imaging BV, the Netherlands).
Western blotting—For BALB/c blots, whole liver lysate was gathered as described above. 
For drug treatments, 1x106 Hepa1–6 cells were seeded in each well of a 6-well plate. Drugs 
or a DMSO control were added to the medium, and cells were incubated for 22 h. Insulin-
transferrin-sodium selenite (ITSS) was then added to the medium for 30 min to stimulate 
cells. Media was aspirated and cells were lysed in an SDS lysis buffer at 4°C for 30 min, 
then at room temperature for 30 min. Lysate was harvested and filtered in AcroPrep 
Advance filter plates (Pall Corporation) spun for 45 min at 3500 rpm. 4x Western Loading 
Dye (Invitrogen) was added and lysates were boiled for 5 min. Proteins were run on Bolt 
4%–12% Bis-Tris Plus gels (Invitrogen), then transferred using the iBlot dry transfer system 
(Invitrogen).
Membranes were briefly rinsed in methanol then blocked for 1 h at room temperature in 
TBS+0.5% Tween-20+5% BSA. Primary antibodies were added and incubated at 4°C 
overnight. All primary antibodies were obtained from Cell Signaling Technologies, and were 
used at a 1:1000 working concentration. Blots were then washed 3x 10 minutes in TBS-
Tween, then incubated in TBS-Tween-BSA with secondary antibodies (anti-mouse 800, 
1:10,000 and anti-rabbit 680, 1:10,000; Li-Cor). Blots were washed a second time, allowed 
to dry, and visualized and analyzed on an Odyssey IR scanner (Li-Cor). Protein levels were 
quantified by measuring IR signal and all data were normalized to μ-actin. Antibodies for p-
RPS6 and b-actin were incubated with and found to have no reactivity against extracellular 
P. yoelii sporozoites or T. gondii tachyzoites (Figure S6).
In vivo treatment and infection—Drugs were prepared by initial suspending in DMSO 
to a stock solution, then diluting the stock in warmed PBS and Tween-80, gently pipetting to 
avoid precipitation. Final vehicle was 2% DMSO+5% Tween-80+drug: BI-D1840 (50 
mg/kg) or LY2584702 tosylate (12.5 mg/kg). Drug was injected intraperitoneally every 24 h 
at days 1, 0, and 1. At day 0, 5x104 P. yoelii GFP-Luc sporozoites were injected via tail vein. 
Liver stage burden of PyGFP-luc development was monitored by in vivo bioluminescence 
imaging (IVIS) as described below.
In vivo bioluminescent imaging of liver-stage development—Luciferase activity 
in animals was visualized through imaging of whole bodies using the in vivo Imaging 
System (Caliper Life Sciences). Mice were injected intraperitoneally with 100 μL of 
RediJect D-Luciferin (Perkin Elmer) prior to being anesthetized using the isoflurane-
anesthesia system (XGI-8, Caliper Life Sciences). Bioluminescence images were acquired 
with a 10 cm field of view, medium binning factor, and an exposure time of 3–5 min. 
Quantitative analysis of bioluminescence was performed by measuring the luminescence 
signal intensity using the region of interest (ROI) settings of the Living Image 3.0 software. 
Glennon et al. Page 12













ROIs were placed around the abdominal area at the location of the liver and background 
luminescence subtracted based on background ROI measurements on the lower abdomen.
QUANTIFICATION AND STATISTICAL ANALYSIS
Innopsis Mapix software was used to quantify lysate array spot signal intensity. Living 
Image 3.0 software was used to quantify luciferase activity in infected mice. An iterative 
Classic Maximum Likelihood Estimation widefield algorithm provided by Huygens 
Professional Software was used to process immunofluorescence images of sporozoites, as 
described in the immunofluorescence microscopy method details section. FlowJo was used 
to visualize and quantify all flow cytometry data. Representative FlowJo plots are shown in 
Figures S1 and S4. GraphPad Prism 7 was used for all statistical analyses. Statistical details 
for each experiment can be found in the figure legends, including the number of technical 
and biological replicates performed.
For in vivo experiments a biological replicate consisted of an individual mouse or, for LS 
size measurement, individual parasites. For in vitro experiments 3 or more biological 
replicates were performed, using separate passages of cells and parasites. For in vitro 
experiments three technical replicates (wells of cells plated, infected, and treated side by 
side) were performed in each biological replicate. For protein lysate arrays quadruplicate 
technical replicates of each biological replicate were printed and the mean signal used. 
Means and individual data points are shown on all bar graphs. Standard error is shown in 
Table 1. Data were analyzed using Student’s t test, linear regression, or Pearson’s 
Correlation Coefficient as indicated in the figure legends. No data points were excluded. P 
value < 0.05 was used as the statistical significance threshold.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• p-RPS6 is elevated in hepatocyte populations susceptible to Plasmodium (Py)
• Inhibiting RPS6 phosphorylation prior to infection decreases Py infection
• In Py-infected hepatocytes, canonical Akt/RPS6 signaling is disrupted
• Response to insulin Is abrogated in Py-infected hepatocytes
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Figure 1. Phosphorylated Ribosomal Protein S6 Is Elevated in P. yoelii-Susceptible Cell 
Populations
(A and B) Log2 fold change in RPPA signal plotted against −log10 p value for each of 62 
antibodies against total or phosphorylated protein in (A) livers of BALB/cJ (n = 10) 
compared to BALB/cJ (n = 10) mice and (B) 8n, compared to 2n, hepatocytes isolated from 
10 BALB/cAnN mice. Signal from each antibody was normalized to β-actin.
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Figure 2. Pre-treatment with S6 Kinase Inhibitors Reduces LS Burden
(A) Schematic showing timing and duration of inhibitor treatment for experiments in (B)–
(F). Treatment regimes indicated in red reduced LS infection.
(B) Hepa1–6 cells were pre-treated with S6K inhibitor BI-D1870 (1 μM) or LY2584702 
(100 nM) for 22 h before and after infection with P. yoelii sporozoites. Cells were collected 
at 90 min, 24 h, and 48 h post-infection (hpi), and infection levels were measured by flow 
cytometry (90 min) or fluorescence microscopy (24 h and 48 h).
(C) Cells were treated with inhibitors for 22 h prior to infection and through invasion. Cells 
were fixed 24 hpi, and parasites were quantified by fluorescence microscopy.
(D) Cells were treated with inhibitors after invasion. Cells were fixed 24 hpi, and parasites 
were quantified by fluorescence microscopy.
(E) Cells were simultaneously treated with inhibitors and infected with P. yoelii sporozoites 
for 90 min, after which cells were washed. Cells were fixed 24 hpi, and parasites were 
quantified by fluorescent microscopy.
(F) Sporozoites were incubated with inhibitors and then washed before being added to 
untreated cells. Cells were fixed 24 hpi, and parasites were quantified by fluorescence 
microscopy. Data were assessed statistically by Student’s t test. Data shown are from one of 
three biological replicates (see Table S2 for data from other biological replicates). Each 
point represents a technical replicate.
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Figure 3. Phosphorylation of RPS6 Is Increased in Infected Hepatocytes
(A–C) Hepa1–6 cells were infected with P. yoelii sporozoites and collected at (A) 3, (B) 6, 
and (C) 24 hpi. p-RPS6 was quantified by flow cytometry in infected and uninfected cells, 
sorted by PyCSP staining. Data were assessed statistically by Student’s t test. Data shown 
are from one of three biological replicates (see Table S2 for data from other biological 
replicates). Each point represents a technical replicate.
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Figure 4. Plasmodium Infection Alters Correlation between Members of the AKT/P70S6K/RPS6 
Cascade
(A) Schematic of canonical signaling pathway leading from insulin stimulation to 
phosphorylation of RPS6.
(B) Cells were treated with insulin or infected with P. yoelii or T. gondii and collected over a 
time course from 3 to 48 h (n = 3). Levels of p-AKT, p-P70S6K, and p-RPS6 were measured 
by RPPA. Signal from each antibody of interest was normalized to b-actin. Fold change in 
RPPA signal between treated and non-treated or infected and uninfected cells is plotted for 
each antibody pair. Each point represents a single sample from a single time point. Pearson 
values (P) were calculated as a measure of correlation between levels of each 
phosphorylated protein. See also Table S2.
Glennon et al. Page 22













Figure 5. Plasmodium Infection Prevents Phosphorylation of RPS6 in Response to Insulin 
Treatment
(A) Fold change in p-RPS6 mean fluorescence intensity (MFI) between uninfected (UI) and 
P. yoelii-infected Hepa1–6 cells 24 hpi. Each point represents a biological replicate.
(B) p-RPS6 MFI of Hepa1–6 cells that were either uninfected or infected with P. yoelii 
sporozoites for 24 h before treatment with insulin or a diluent control for 30 min. Data 
shown are from one of three biological replicates (see Table S2 for data from other 
biological replicates). Each point is a technical replicate.
(C) Fold change in p-RPS6 mean fluorescence intensity (MFI) between uninfected and T. 
gondii-infected Hepa1–6 cells 24 hpi. Each point represents a biological replicate.
(D) p-RPS6 MFI of Hepa1–6 cells that were uninfected or infected with T. gondii for 24 h 
before treatment with insulin for 30 min. Data shown are from one of three biological 
replicates (see Table S2 for data from other biological replicates). Each point is a technical 
replicate. Data were assessed statistically by Student’s t test.
(E) Schematic of proposed signaling pathways leading to phosphorylation of RPS6 in 
uninfected, Toxoplasma-infected, and Plasmodium-infected cells.
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Table 1.
Top Differentially Regulated Total and Phosphorylated Proteins in Susceptible Cell Types
Antibody Fold Change SE p Value
BALB cByJ/cJ Upregulated
RPS6 (pS235/236) 1.477 0.041 0.027
SOD2 1.548 0.065 0.042
DUSP4 1.231 0.075 0.061
Glycogen synthase (pS641) 1.296 0.117 0.091
8n/2n Upregulated
RPS6 (pS236/236) 2.359 0.074 0.017
EGFR 1.297 0.064 0.049
Dvl3 1.634 0.067 0.077
Heregulin 1.200 0.016 0.080
SOD2 1.460 0.086 0.085
BALB cByJ/cJ Downregulated
Jak2 0.765 0.084 0.109
8n/2n Downregulated
EIF4E 0.253 0.072 0.078
FAK (pY397) 0.793 0.062 0.078
ERK (pT202/Y204) 0.311 0.142 0.089
PTEN 0.349 0.127 0.100
Twenty percent fold change and a p value of 0.1 or less were used as cutoffs for inclusion in this table. For the complete dataset, see Table S1.
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